



Amaxa® Cell Line Nucleofector® Kit L

For HeLa S3 [ATCC® CCL-2.2™, cryopreserved]


Human cervix adenocarcinoma; adherent epithelial cell line

Example for Nucleofection® of HeLa S3 cells





HeLa S3 cells [ATCC® CCL-2.2[™]] were transfected using the Cell Line Nucleofector® Kit L, program V-001 and 2 μg of pmaxGFP® Vector. 24 hours post Nucleofection® cells were analyzed by light [A] and fluorescence microscopy (B).



Average transfection efficiency and viability of HeLa S3 cells. HeLa S3 ATCC® CCL-2.2 $^{\rm m}$] cells were transfected using Nucleofector $^{\rm m}$ Program V-001 and 2 μ g of pmaxGFP $^{\rm m}$ Vector. 24 hours post Nucleofection $^{\rm m}$ cells were analyzed by flow cytometry. Cell viability was determined as % PI negative cells.

Product Description

Cat. No.		VCA-1005
Size (reactions)		25
Cell Line Nucleofector® Solution L		2.25 ml (2.05 ml + 10% overfill)
Supplement		0.5 ml (0.45 ml + 10% overfill)
pmaxGFP® Vector (0.5 µg/µl in 10 mM Tris pH 8.0)		30 µg
Certified cuvettes		25
Plastic pipettes		25
Storage and stability	Store Nucleofector® Solut	ion, Supplement and pmaxGFP® Vector at 4°C. For long-term storage,

Store Nucleofector® Solution, Supplement and pmaxGFP® Vector at 4°C. For long-term storage, pmaxGFP® Vector is ideally stored at -20°C. The expiration date is printed on the solution box. Once the Nucleofector® Supplement is added to the Nucleofector® Solution it is stable for three months at 4°C.

Optimized Protocol for HeLa S3 [ATCC®]

Required Material

Note

Please make sure that the entire supplement is added to the Nucleofector® Solution. The ratio of Nucleofector® Solution to supplement is 4.5:1. For a single reaction use 82 µl of Nucleofector® Solution plus 18 µl of supplement to make 100 µl of total reaction volume.

- Nucleofector® Device
- Supplemented Nucleofector® Solution at room temperature
- Supplied certified cuvettes
- Supplied plastic pipettes
- Supplied pmaxGFP® Vector
- Substrate of interest, highly purified, preferably by using endotoxin free Kits; A260: A280 ratio should be at least 1.8
- 12-well culture dish or culture system of your choice
- For detaching cells: 0.5 mg/ml trypsin; 0.2 mg/ml EDTA in PBS and supplemented culture media or PBS/0.5% BSA
- Culture medium: Ham's F12K media with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 90% [ATCC® 30-2004]; fetal bovine serum, 10% [ATCC® 30-2020])
- Prewarm appropriate volume of culture medium to 37°C (1.5 ml per sample)
- Appropriate number of cells (1 x 10⁶ cells per sample); lower or higher cell numbers may influence transfection results

1. Pre Nucleofection®

Cell culture recommendations

- 1.1 Replace media every 2 3 days
- 1.2 Cells should be passaged three times a week
- 1.3 Seed out $2 3 \times 10^6$ cells per T162 flask
- 1.4 For Nucleofection® cells should be passaged 1 day before
- 1.5 Cells will not reach a 100% confluency growing in a flask

Trypsinization

- 1.6 Remove media from the cultured cells and wash cells once with PBS; use at least same volume of PBS as culture media
- 1.7 For harvesting, incubate the cells at 37°C with e.g. 0.5 mg/ml trypsin; 0.2mg/ml EDTA in PBS
- 1.8 Inactivate trypsinization reaction with supplemented culture media or PBS/0.5% BSA

Optimized Protocol for HeLa S3 [ATCC®]

2. Nucleofection®

One Nucleofection® Sample contains

1 x 106 cells

 $1-2 \mu g$ plasmid DNA (in $1-5 \mu l$ H₂0 or TE) or 2 μg pmaxGFP® Vector or 30 - 300 nM siRNA (3 - 30 pmol/sample)

100 µl Cell Line Nucleofector® Solution L

- 2.1 Please make sure that the entire supplement is added to the Nucleofector® Solution
- 2.2 Prepare 12-well plates by filling appropriate number of wells with 1.5-2 ml of supplemented culture media and pre-incubate/equilibrate plates in a humidified 37° C/5% CO₂ incubator
- 2.3 Harvest the cells by trypsinization (please see 1.6 1.8)
- 2.4 Count an aliquot of the trypsinized cells and determine cell density
- 2.5 Centrifuge the required number of cells (1 x 10^6 cells per sample) at 90xg for 10 minutes at room temperature
- 2.6 Resuspend the cell pellet carefully in 100 µl room temperature Nucleofector® Solution per sample
- 2.7 Combine 100 μ l of cell suspension with 1 2 μ g DNA or 30 nM 300 nM siRNA 3 30 pmol/sample) or other substrates
- 2.8 Transfer cell/DNA suspension into certified cuvette (sample must cover the bottom of the cuvette without air bubbles). Close the cuvette with the cap
- 2.9 Select the appropriate Nucleofector® Program V-001 (V-01 for Nucleofector® I Device)
- 2.10 Insert the cuvette with cell/DNA suspension into the Nucleofector® Cuvette Holder and apply the selected program
- 2.11 Take the cuvette out of the holder once the program is finished
- 2.12 Add ~500 µl of the pre-equilibrated culture media to the cuvette and gently transfer the sample immediately into the 12-well plate (final volume 1.5 ml media per well/sample). Use the supplied pipettes and avoid repeated aspiration of the sample

3. Post Nucleofection®

3.1 Incubate the cells in a humidified $37^{\circ}\text{C/5}\%$ CO₂ incubator until analysis. Gene expression is often detectable already after only 4-8 hours

Additional Information

For an up-to-date list of all Nucleofector® References, please refer to: www.lonza.com/nucleofection-citations

For more technical assistance, contact our Scientific Support Team:

 USA/Canada
 Europe and Rest of World

 Phone:
 800 521 0390 (toll-free)
 Phone: +49 221 99199 400

 Fax:
 301 845 8338
 Fax: +49 221 99199 499

References

1. Johnson JL et al, Traffic 2005; 6(8): 667-681. 2. Voss OH et al, J Biol Chem 2005; 280(17): 17371-17379

Lonza Cologne AG 50829 Cologne, Germany

 $Please \ note that \ the \ Amaxa^{\circledcirc} \ Nucleo fector ^{\circledcirc} Technology \ is \ not intended \ to \ be used for \ diagnostic purposes \ or for testing \ or \ treatment \ in \ humans.$

Te Nucleofector® Technology, comprising Nucleofection® Process, Nucleofector® Device, Nucleofector® Solutions, Nucleofector® 96-well Shuttle® System and 96-well Nucleocuvette® plates and modules is covered by patent and/or patent-pending rights owned by Lonza Cologne AG.

Amaxa, Nucleofector, Nucleofection and maxGFP are either registered trademarks or trademarks of the Lonza Cologne AG in Germany and/or U.S. and/or other countries.

ATCC $^{\rm o}$ and the ATCC $^{\rm o}$ Catalog Marks are trademarks of ATCC $^{\rm o}$.

 $Other \, product \, and \, company \, names \, mentioned \, herein \, are \, the \, trademarks \, of \, their \, respective \, owners.$

This kit contains a proprietary nucleic acid coding for a proprietary copepod fluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at license@evrogen.com.

The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.

The use of this product in conjunction with materials or methods of third parties may require a license by a third party. User shall be fully responsible for determining whether and from which third party it requires such license and for the obtainment of such license.

No statement is intended or should be construed as a recommendation to infringe any existing patent.

@ Copyright 2009, Lonza Cologne AG. All rights reserved DCC-1003 05/09